Rosuvastatin attenuates inflammation, apoptosis and fibrosis in a rat model of cyclosporine-induced nephropathy. 2013

Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
Department of Internal Medicine, Busan Medical Center, Busan, Republic of Korea.

OBJECTIVE Cyclosporine (CsA)-induced kidney injury is characterized by renal dysfunction with inflammatory cell infiltrations, apoptosis and fibrosis. Pleiotropic effects of statins may exert anti-inflammatory, antiapoptotic and antifibrotic actions beyond lipid control. The aim of this study is to investigate whether rosuvastatin (RUS) has anti-inflammatory, antiapoptotic and antifibrotic effects on chronic CsA-induced nephropathy in a rat model. METHODS Male Sprague-Dawley rats fed a low-sodium diet were divided into three treatment groups: control (0.9% saline injection), CsA (15 mg/kg/day by subcutaneous injection), CsA + RUS (10 mg/kg/day by gastric gavage). Renal function, CsA level and lipid levels were measured at the end of 4 weeks. The expression of ED-1, transforming growth factor-β(1) (TGF-β(1)) and α-smooth muscle actin (α-SMA) for inflammation and fibrosis were examined by Western blot analysis. The expression levels of apoptosis-associated factors were examined by Western blot analysis. Apoptosis was evaluated using the terminal deoxynucleotidyl transferase-mediated biotin nick end-labeling (TUNEL) method. RESULTS Kidney function was decreased in CsA-treated rats compared with controls, which was attenuated by RUS. RUS did not affect the lipid level or the blood CsA level. TUNEL staining showed that RUS inhibited CsA-induced tubular apoptosis. RUS decreased CsA-induced increased expression of Bax/Bcl-2 ratio. The expressions of ED-1, α-SMA, TGF-β(1), Smad2/3, Smad4 and p-JNK were increased in CsA-treated rats, which were attenuated by RUS. Tubular atrophy and interstitial fibrosis in CsA-treated rats were attenuated by RUS supplementation. CONCLUSIONS RUS supplementation attenuates proinflammatory and apoptosis-related factors and inhibits the fibrotic pathways including the smad-dependent and smad-independent pathways in a rat model of CsA-induced nephropathy.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008297 Male Males
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005464 Fluorobenzenes Derivatives of BENZENE that contain FLUORINE. Fluorobenzene
D000068718 Rosuvastatin Calcium A HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for CARDIOVASCULAR DISEASES. Crestor,Rosuvastatin,ZD 4522,ZD4522,Calcium, Rosuvastatin
D000199 Actins Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle. F-Actin,G-Actin,Actin,Isoactin,N-Actin,alpha-Actin,alpha-Isoactin,beta-Actin,gamma-Actin,F Actin,G Actin,N Actin,alpha Actin,alpha Isoactin,beta Actin,gamma Actin

Related Publications

Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
January 2004, American journal of physiology. Renal physiology,
Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
August 1995, Kidney international,
Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
August 2014, Molecular medicine reports,
Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
September 2012, Journal of cardiovascular pharmacology and therapeutics,
Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
August 2013, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology,
Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
June 2015, The Journal of urology,
Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
October 2019, Life sciences,
Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
August 2011, Molecular and cellular biochemistry,
Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
October 2019, Transplantation,
Hyun Kyung Nam, and Seong Joo Lee, and Moo Hyun Kim, and Jee Hyun Rho, and Young Ki Son, and Su Mi Lee, and Seong Eun Kim, and Ki Hyun Kim, and Won Suk An
June 2005, Transplantation,
Copied contents to your clipboard!